The introduction of immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; United States only), as well as BRAF/MEK …
China has the highest incidence of gastroesophageal cancer globally, and therapeutic options are limited. Only five targeted agents are approved for treatment—trastuzumab (Roche’s Herceptin,…
The wet age-related macular degeneration (AMD) therapy market has long been dominated by three VEGF inhibitors—Roche / Genentech / Chugai’s Avastin, Roche / Genentech / Novartis’s Lucentis,…
Bladder cancer is the eighth most commonly diagnosed cancer in China. The bladder cancer therapy market is set to enter a competitive and dynamic period of rapid growth, fueled by one of the most…
Chemotherapy remains the dominant cornerstone of colorectal cancer treatment and is prescribed with angiogenesis or EGFR inhibitors in the metastatic setting. Patient biomarker status (e.g., BRAF,…
Breast cancer is the most commonly diagnosed cancer in women in China. The disease has been managed primarily through chemotherapy in China, but several novel, premium-priced targeted therapies—…
Chemotherapy and hormonal therapy have been the mainstay treatments of advanced endometrial carcinoma, but treatment is becoming more directed, as a result of tumor analysis. Immune checkpoint…
DRG Epidemiology's coverage of hepatitis C comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of hepatitis…
Clarivate Epidemiology’s coverage of hepatitis c virus (HCV) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and prevalence of HCV for…
Clarivate Epidemiology’s coverage of hepatitis c virus (HCV) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and prevalence of HCV for…
Clarivate Epidemiology’s coverage of hepatitis Cc virus (HCV) comprises epidemiological estimates of key patient populations inacross 45 countries worldwide. We report both the incidence and…
DRG Epidemiology’s coverage of hepatitis C virus (HCV) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of HCV…
DRG Epidemiology’s coverage of hepatitis C virus (HCV) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of HCV…
The treatment landscape for squamous cell carcinoma of the head and neck (SCCHN) witnessed a major change in 2019 with the approval of Merck & Co.’s Keytruda for untreated recurrent or metastatic…
The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants drive further shifts in a complicated treatment…